A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples